Peroxisome proliferator-activated receptor γ-dependent and -independent growth inhibition of gastrointestinal tumour cells

Genes to Cells

Volumn 9, Issue 11, 2004, Pages 1113-1123

  Rumi, M Azharul Karim ^a   Ishihara, Shunji ^a   Kadowaki, Yasunori ^a   Ortega Cava, C F ^a   Kazumori, Hideaki ^a   Kawashima, Kousaku ^a   Yoshino, Nagisa ^a   Yuki, Takafumi ^a   Ishimura, Norihisa ^a   Kinoshita, Yoshikazu ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; HORMONE RECEPTOR BLOCKING AGENT; LUCIFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; THYMIDINE; TRITIUM; TROGLITAZONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DRUG EFFECT; GASTROINTESTINAL TUMOR; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REPORTER GENE; TRANSCRIPTION INITIATION; TUMOR CELL LINE; TUMOR GROWTH;

BASE SEQUENCE; CELL DIVISION; CELL LINE, TUMOR; DNA PRIMERS; DNA, COMPLEMENTARY; ENZYME ACTIVATION; GASTROINTESTINAL NEOPLASMS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PPAR GAMMA; THIAZOLIDINEDIONES; TRANS-ACTIVATION (GENETICS); TRANSFECTION;

EID: 7944225005     PISSN: 13569597     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2443.2004.00793.x     Document Type: Article

References (40)

1. Adams, M., Reginato, M.J., Shao, D., Lazar, M.A. & Chatterjee, V.K. (1997) Transcriptional activation by peroxisome proliferator-activated receptor γ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J. Biol. Chem. 272, 10811-10816.
2. Beak, S.J., Wilson, L.C., His, L.C. & Eling, T.E. (2003) Troglitazone, a peroxisome proliferators activated receptor γ (PPARγ) ligand, selectively induces early growth response-1 gene independently of PPARγ. A novel mechanism for its anti-tumorigenic activity. J. Biol. Chem. 278, 5845-5853.
3. Brockman, J.A., Gupta, R.A. & DuBois, R.N. (1998) Activation of PPARγ leads to inhibition of anchorage independent growth of human colorectal cancer cells. Gastroenterology 115, 1049-1055.
4. Camp, H.S., Tafuri, S.R. & Leff, T. (1999) c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor γ 1 and negatively regulates its transcriptional activity. Endocrinology 140, 392-397.
5. Chung, S.W., Kang, B.Y., Kim, S.H., et al. (2000) Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor γ and nuclear factor κB. J. Biol. Chem. 275, 32681-32687.
6. 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83 803-812.
7. Girnun, G.D., Smith, W.M., Drori, S., et al. (2002) APC-dependent suppression of colon carcinogenesis by PPARγ. Proc. Natl. Acad. Sci. USA 99, 13771-13776.
8. Gupta, R.A., Brockman, J.A., Sarraf, P., Willson, T.M. & Dubois, R.N. (2001) Target genes of peroxisome proliferator-activated receptor γ in colorectal cancer cells. J. Biol. Chem. 276, 29681-29687.
9. Gurnell, M., Wentworth, J.M., Agostini, M., et al. (2000) A dominant-negative peroxisome proliferator activated receptor γ (PPARγ) mutant is a constitutive repressor and inhibits PPARγ-mediated adipogenesis. J. Biol. Chem. 275, 5754-5759.
10. Haraguchi, K., Shimura, H. & Onaya, T. (2002) Activation of peroxisome proliferator-activated receptor-γ inhibits apoptosis induced by serum deprivation in LLC-PK1 cells. Exp. Nephrol. 10, 393-401.
11. He, T.C., Chan, T.A., Vogelstein, B. & Kinzler, K.W. (1999) PPARγ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99, 335-345.
12. Heaney, A.P., Fernando, M., Young, W.H. & Melmed, S. (2002) Functional PPARγ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat. Med. 8, 1281-1287.
13. Kim, J.A., Park, K.S., Kim, H.I., et al. (2002) Troglitazone activates p21Cip/WAF1 through the ERK pathway in HCT15 human colorectal cancer cells. Cancer Lett. 179, 185-195.
14. Kishida, K., Shimomura, I., Nishizawa, H., et al. (2001) Enhancement of aquaporin adipose gene expression by peroxisome proliferator-activated receptor γ. J. Biol. Chem. 276, 48572-48579.
15. Kliewer, S.A., Sundseth, S.S., Jones, S.A., et al. (1997) Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptor (α and γ. Proc. Natl. Acad. Sci. USA 94, 4318-4323.
16. Kliewer, S.A., Umesono, K., Noonaan, D.J., Heyman, R.A. & Evans, R.M. (1992) Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358, 771-774.
17. Koeffler, H.P. (2003) Peroxisome proliferators-activated receptor γ and cancers. Clin. Cancer Res. 9, 1-9.
18. Kroll, T.G., Sarraf P., Pecciarini, L., et al. (2000) PAX-8-PPARγ1 fusion oncogene in human thyroid carcinoma [Published erratum appears in Science 289, 1474, 2000]. Science 289, 1357-1360.
19. Kubota, T., Koshizuka, K., Williamson, E.A., et al. (1999) Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 58, 3344-3352.
20. Leesnitzer, L.M., Parks, D.J., Bledsoe, R.K., et al. (2002) Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41, 6640-6650.
21. min/+ mice. Nat. Med. 4, 1053-1057.
22. Lehmann, J.M., Moore, L.B., Smith-Oliver, T.A., Wilkison, W.O., Willson, T.M. & Kliewer, S.A. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270 12953-12956.
23. Lehmann, J.M., Lenhard, J.M., Oliver, B.B., Ringold, G.M. & Kliewer, S.A. (1997) Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other nonsteroidal anti-inflammatory drugs. J. Biol. Chem. 272, 3406-3410.
24. Lucarelli, E., Sangiori, L., Maini, V., et al. (2002) Troglitazone affects survival of human osteosarcoma cells. Int. J. Cancer 98, 344-351.
25. Motomura, W., Okumura, T., Takahashi, N., Obara, T. & Khogo, Y. (2000) Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p27Kip1 in human pancreatic carcinoma cells. Cancer Res. 60, 5558-5564.
26. Muller, E., Smith, M., Sarraf, P., et al. (2000) Effects of ligand activation of peroxisome proliferator-activated receptor γ human prostate cancer. Proc. Natl. Acad. Sci. USA. 97, 10990-10995.
27. Osawa, E., Nakajima, A., Wada. K., et al. (2003) Peroxisome proliferators activated receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 124, 361-367.
28. Palakurthi, S.S., Aktas, H., Grubissich, L.M., Mortensen, R.M. & Halperin, J.A. (2001) Anticancer effects of thiazolidinediones are independent of PPARγ and mediated by inhibition of translation initiation. Cancer Res. 61, 6213-6218.
29. Panigrahy, D., Singer, S., Shen, L.Q., et al. (2002) PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J. Clin. Invest. 100, 923-932.
30. Patel, L., Pass, I., Coxon, P., Downes, C.P., Smith, S.A. & Macphee, C.H. (2001) Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN. Curr. Biol. 11, 764-768.
31. Rosen, E.D. & Spiegelman, B.M. (2001) PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 276, 37731-37734.
32. Rumi, M.A., Sato, H., Ishihara, S., et al. (2001) Peroxisome proliferator-activated receptor γ ligand induced growth inhibition of human hepatocellular carcinoma. Br. J. Cancer 84 1640-1647.
33. Rumi, M.A., Sato, H., Ishihara, S., Ortega, C., Kadowaki, Y. & Kinoshita, Y. (2002) Growth inhibition of esophageal squamous carcinoma cells by peroxisome proliferator-activated receptor-γ ligands. J. Lab. Clin. Med. 140, 17-26.
34. Saez, E., Tontonoz, P., Nelson, M.C., et al. (1998) Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat. Med. 4, 1058-1061.
35. Sarraf, P., Mueller, E., Jones, D., et al. (1998) Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat. Med. 4, 1046-1052.
36. Sarraf, P., Mueller, E., Smith, W.M., et al. (1999) Loss-of-function mutations in PPARγ associated with human colon cancer. Mol. Cell 3, 799-804.
37. Suzawa, M., Takada, I., Yanagisawa, J., et al. (2003) Cytokines suppress adipogenesis and PPARγ function through the TAK1/TAB1/NIK cascade. Nat. Cell Biol. 5, 224-230.
38. Takahashi, N., Okumura, T., Motomura, W., Fujimoto, Y., Kawabata, I. & Kohgo, Y. (1999) Activation of PPARγ inhibits cell growth and apoptosis in human gastric cancer cells. FEBS Lett. 455, 135-139.
39. Takeda, K., Ichiki, T., Tokunou, T., Iino, N. & Takeshita, A. (2001) 15-deoxy-delta12, 14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. J. Biol. Chem. 276, 48950-48955.
40. Tontonoz, P., Singer, S., Forman, B.M., et al. (1997) Terminal differentiation of human liposarcoma cells by ligands for peroxisome proliferator-activated receptor γ and retinoid X receptor. Proc. Natl. Acad. Sci. USA 94, 237-241.